Comparative Pharmacology
Head-to-head clinical analysis: DOSTINEX versus PARLODEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOSTINEX versus PARLODEL.
DOSTINEX vs PARLODEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cabergoline is a long-acting dopamine D2 receptor agonist that inhibits prolactin secretion by binding to D2 receptors on lactotroph cells in the anterior pituitary.
Dopamine D2 receptor agonist; inhibits prolactin secretion by binding to pituitary and hypothalamic D2 receptors.
0.25 mg orally twice weekly, with a minimum of 2 days between doses; may increase by 0.25 mg twice weekly every 4 weeks up to a maximum of 1 mg twice weekly.
Parkinson disease: initial 1.25 mg orally twice daily, increase by 2.5 mg/day every 2-4 weeks; usual range 15-30 mg/day. Hyperprolactinemia: initial 1.25-2.5 mg orally once daily, titrate to 2.5 mg twice daily; maintenance 2.5-15 mg/day.
None Documented
None Documented
The terminal elimination half-life is 63–69 hours in healthy volunteers and 79–115 hours in patients with hyperprolactinemia, allowing once- or twice-weekly dosing. The long half-life reflects slow dissociation from D2 receptors and enterohepatic recirculation.
Terminal elimination half-life: 12-14 hours (biphasic, initial half-life 6-8 hours); clinical context: steady-state achieved in 2-3 days.
Cabergoline is extensively metabolized in the liver, primarily via CYP3A4. Elimination is predominantly fecal (60%) and renal (20%) as metabolites, with <4% as unchanged drug. Biliary excretion contributes to fecal elimination.
Renal: approximately 60% as metabolites, 6% as unchanged drug; biliary/fecal: approximately 40% as metabolites and unchanged drug.
Category C
Category C
Dopamine Agonist
Dopamine Agonist